New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
12:50 EDTAGN, VRXPershing Square reveals six nominees to Allergan board
Pershing Square announced a slate of six independent directors for the board of directors of Allergan (AGN). The six members of the slate are: Betsy Atkins, Cathleen Black, Fredric Eshelman, Steven Shulman, David Wilson and John Zillmer. Pershing stated, "As previously announced, Pershing Square is seeking to call a special meeting of Allergan shareholders. At this special meeting, Allergan shareholders will be able to voice their support for a number of critical matters, including the removal of six incumbent members of the Allergan board, the appointment of the independent Pershing Square slate and certain other actions to improve the corporate governance of Allergan. To that end, Pershing Square will file today revised preliminary solicitation materials with the Securities and Exchange Commission." Pershing Square CEO Bill Ackman said, "Each member of our slate of nominees is an independent, skilled leader with relevant domain, industry and/or executive management experience. By supporting this slate, Allergan shareholders can ensure that the interests of shareholders will be well represented on the board of Allergan." Each of the executives is also independent of Pershing Square and Valeant Pharmaceuticals (VRX), Pershing noted.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 21, 2014
12:43 EDTAGNMeister says passive holder of Allergan, aligned with Pershing Square
Subscribe for More Information
07:42 EDTAGN, VRXValeant Q3 results makes strong case for Allergan purchase, says Susquehanna
Subscribe for More Information
06:33 EDTVRX, AGNValeant price target raised to $182 from $167 at Cantor
Subscribe for More Information
October 20, 2014
12:23 EDTAGN, VRXAllergan holder Paulson encourages deal with Shire, Reuters says
Subscribe for More Information
09:25 EDTVRX, AGNValeant says talks to Ackman 'frequently'
Subscribe for More Information
09:08 EDTVRX, AGNValeant says not planning to walk away from Allergan deal before Dec. 18
Subscribe for More Information
08:58 EDTAGN, VRXValeant says still willing to improve bid for Allergan
Valeant (VRX) said would raise Allergan (AGN) bid "when time is right." Says hopes Allergan shareholders see that Valeant's operating model does work and will continue to work. Says Valeant (VRX), Allergan have "unique" business overlap. Says company "should" own Allergan. Says interests with Pershing, Ackman "aligned" on Allergan.
08:37 EDTAGN, VRXValeant says 'completely focused' on Allergan acquisition
Subscribe for More Information
07:34 EDTAGN, VRXValeant says remains focused on completing Allergan transaction
Subscribe for More Information
07:32 EDTVRXValeant narrows FY14 revenue view to $8.1B-$8.3B from $8B-$8.3B
Subscribe for More Information
07:30 EDTAGN, VRXValeant CEO says 'can bid more than anyone' in financially sound Allergan deal
Pearson says "we cannot stop" another company from making a bid that does not make economic sense, but he believes Valeant (VRX) can "bid more than anyone" for Allergan (AGN) in a deal that makes financial sense. Pearson says he has met with doctor groups and that 95% of those he's spoken with support Valeant's bid for Allergan. Valeant CEO J. Michael Pearson spoke on CNBC.
07:28 EDTVRXValeant raises FY14 cash EPS to $8.22-8.32 from $7.90-$8.10
Subscribe for More Information
07:16 EDTAGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:06 EDTVRXValeant raises FY15 outlook cash EPS $10.00 from $9.90
Subscribe for More Information
07:05 EDTVRXValeant raises Q4 cash EPS $2.45-$2.55 from $2.35-$2.45
Subscribe for More Information
07:03 EDTVRXValeant reports Q3 cash EPS $2.11, Q3 GAAP EPS 81c
Reports Q3 revenue revenue $2.1B; Reports Q3 total same store sales organic growth 19%. Bausch + Lomb organic growth was 12%. Q3 GAAP Operating Cash Flow $619 million, an increase of 207%; Adjusted Operating Cash Flow $771 million, an increase of 89%
06:28 EDTAGNAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTAGN, VRXValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTAGNAllergan not in deal talks with Actavis, CNBC reports
09:43 EDTAGN, VRXValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use